Latest news with #RCT
Wales Online
a day ago
- Health
- Wales Online
Popular councillor resigns after being diagnosed with a brain tumour
Popular councillor resigns after being diagnosed with a brain tumour Dawn Wood said she has been forced to step down 'because of significant health challenges linked to a brain tumour' Dawn Wood has stepped down from her councillor roles (Image: Pontypridd Town Council ) A popular councillor has resigned due to ill health after being diagnosed with a brain tumour. Dawn Wood served as the RCT councillor for Pontypridd Town ward and Pontypridd Town councillor but had been absent from her roles since December 2024 for "medical reasons". She was elected as the Plaid Cymru councillor for Pontypridd Town in May 2022. Cllr Wood will be stepping down from both her roles with immediate effect. She said that it "was not an easy decision to make", adding that she was "devastated" to be making the announcement. "As many of you will be aware, I've had to take a period of absence from my role as both your RCT Councillor and Pontypridd Town Councillor for the past few months because of significant health challenges linked to a brain tumour," she said in a statement on Wednesday. "Thank you for all your kind words, support and understanding during this time. After careful consideration and consultation with my medical team, I have come to the difficult decision that I must step down from my role to focus on my health and wellbeing and have therefore tendered my resignation with immediate effect." She said serving the residents of Pontypridd Town Ward "has been one of the greatest honours" of her life. "I am deeply grateful for the trust and support that the community has shown me over the past three years. It has been a privilege to work alongside my fellow Plaid Cymru councillors and so many individuals, businesses and community groups to make a positive impact on our community." Cllr Ward explained that she had come to the difficult decision because of her "poor" prognosis. "Unfortunately, all avenues for treatment have been explored and my prognosis now is unfavourable, and is especially poor, if I were to continue in this role," she said. Article continues below "This was not an easy decision to make, but I hope you will understand why it is necessary." Get the latest Ponty news first by signing up to our newsletter here Cllr Ward spent nearly 30 years as a teacher before becoming a councillor and is also one half of the couple behind Between The Trees - a festival which combines indie folk music, art, and spoken word to inspire creativity and reconnect attendees with natural world. You can read more about this here. Cllr Ward's constituents and colleagues from across various parties thanked her for the work she had done. Labour MP for Pontypridd Alex Davies-Jones said: "I am very sorry to hear of Dawn Wood's resignation as councillor for Pontypridd Town Ward. "Although we come from different political parties, Dawn and I have worked closely together over the past few years, always with the shared goal of doing what's best for our community. I know this can't have been an easy decision, and I want to thank her for the time and commitment she gave to the role. "I'm thinking of her at this incredibly difficult time and wish her strength and all the very best for the future. She will be missed." Heledd Fychan, Plaid Cymru Ms for South Wales Central and Pontypridd Town Councillor said: "Cllr Dawn Wood has been an incredible colleague and champion for Pontypridd Town ward, and I'm saddened by this news. But as her friend, I'm fully supportive of her decision to prioritise her health. "Diolch am bopeth Dawn. You have been a bright light in our community and in the council chamber. If residents require support, I remain a representative on Pontypridd Town Council and as one of your Senedd Members. Please feel free to get in touch." One constituent wrote on Facebook: "Your health is the priority Dawn but thank you for all the support that you've given us and the wider community. You've been an asset." Another said: "Many thanks for all your hard work as our councillor. You have been very proactive and a real asset to Pontypridd town. Take care of yourself." A by-election is expected to be held to elect a replacement for the RCT council and Pontypridd Town Council seat in due course. Article continues below
Yahoo
5 days ago
- General
- Yahoo
Need a ride to Final Fridays? Mansfield's free shuttle comes to your door
Richland County Transit will offer free rides for Final Fridays in downtown Mansfield. According to an announcement, the service will run from 6:30 p.m. to 11 p.m. on May 30, June 27, July 25, Aug. 29 and Sept. 26. RCT drivers will provide door-to-door rides in small buses, similar to Dial-A-Ride. The service area will include most of Lexington, Ontario and Madison Township, along with all of Mansfield. Rides must start or end at the pickup location on North Diamond Street near the Brickyard. To schedule a pickup, call RCT at 419-522-4504. Advance reservations are encouraged, but same-day requests may be accommodated based on availability. The Final Friday shuttle service is supported by RCT and the City of Mansfield. For more information, visit This story was created by Jane Imbody, jimbody@ with the assistance of Artificial Intelligence (AI). Journalists were involved in every step of the information gathering, review, editing and publishing process. Learn more at or share your thoughts at with our News Automation and AI team. This article originally appeared on Mansfield News Journal: Free door-to-door rides offered for Mansfield's Final Fridays
Yahoo
30-05-2025
- Business
- Yahoo
Moximed announces treatment of first subject in trial of knee system
Moximed has announced the treatment of the first subject in the multi-centre MOTION randomised controlled trial (RCT) assessing its MISHA knee system against non-surgical treatment in individuals with medial knee osteoarthritis (OA). This prospective trial is designed to assess the benefits of the MISHA system compared with non-surgical treatment options endorsed by the American Academy of Orthopaedic Surgeons (AAOS) Clinical Practice Guidelines. These include physical therapy, weight management, physical conditioning, intra-articular injections, assistive devices, and various medications. At least 100 participants will be randomised in the trial, which is currently enrolling at approximately ten sites across the US. Enrolment locations include RUSH University Medical Center, NYU Langone Health, and Scripps Health. The primary endpoint of the study is the improvement in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score. In 2023, the MISHA knee system secured marketing authorisation from the US Food and Drug Administration (FDA). The system claims to have demonstrated superiority to high tibial osteotomy (HTO) in two years after the operation. It is specifically designed for those who have not found relief from previous treatments and are either ineligible for or unwilling to undergo joint replacement surgery. Knee OA is said to arise when the joint's natural shock absorbers, the cartilage and meniscus, fail to cushion it, resulting in chronic pain and restricted activity. Moximed noted that as the first implantable shock absorber for the knee, the MISHA system minimises the load on the joint while walking, potentially alleviating pain, preserving joint function, and delaying the need for replacement surgery. The device is implanted on the medial knee and is engineered to move in harmony with the joint, decreasing 30% of the peak force exerted on the knee during walking. Moximed CEO and president Christopher Gleason said: 'Knee OA patients across the country are looking for an effective and less invasive treatment option without activity restrictions. 'The growing commercial adoption of the MISHA knee system reflects the confidence that physicians and patients have in this breakthrough treatment.' "Moximed announces treatment of first subject in trial of knee system" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Wales Online
21-05-2025
- Wales Online
Woman prosecuted after barking dogs made neighbour's life a misery
Woman prosecuted after barking dogs made neighbour's life a misery A neighbour made 225 recordings of dogs barking over a three-month period A pet owner whose barking dogs made her neighbour's life a misery has been ordered to pay more than £1,500 for repeatedly ignoring warnings to keep the noise down. A court was told that a neighbour submitted a total of 225 recordings of the dogs barking within a three-month period. Merthyr Tydfil Magistrates' Court heard that Keira Marsh, from Porth, continuously allowed her dogs to bark, causing distress to her neighbours. After Rhondda Cynon Taf Council received a number of sound recordings from the complainant an investigation was launched. Environmental health officers visited the complainant's property and witnessed the "continuous barking" for themselves. They were satisfied a statutory noise nuisance existed, which means that the noise was severe enough to cause prejudice to health and/or an unreasonable and persistent disturbance to interfere with a person's enjoyment of their property. Marsh was then served with an abatement notice, which may require a person to stop the activity to avoid causing a nuisance. Get the latest Rhondda news first by signing up to our newsletter here. But Marsh ignored repeated requests from the council to deal with the issue and failed to attend interviews at council offices. After the 225 recordings of the barking over a three-month period was provided by the complainant the case went to court. Article continues below The council said the evidence "demonstrated that multiple dogs were left to bark for prolonged periods of time and the abatement notice had been breached". Marsh failed to attend the hearing at Merthyr Tydfil Magistrates' Court. She was found guilty in her absence of breaching the abatement notice on six separate occasions, thereby contravening section 80(4) of the Environmental Protection Act 1990. Marsh received a £300 fine and was ordered to pay £1,115.27 in costs and a victim surcharge of £120 – totalling £1,535.27. RCT cabinet member and councillor Bob Harris said: "The council's environmental health team investigates noise complaints and, when officers have evidenced the noise constitutes a statutory nuisance, we always try to work positively with the subject of the complaint to offer advice and guidance on how to deal with the issue. "In this case the council's efforts to find a solution to the problem were repeatedly ignored leaving officers no other option than to prosecute." A council spokesman added: "The occasional bark or 'woof' is usually not a problem for neighbours and others in the community but when barking becomes excessive it's often considered unacceptable and can materially interfere with use of a person's property. Article continues below "The dog's welfare may also be compromised but the owner may not realise their dog has been barking if they're not around at that time." People are encouraged to speak to their owner about the issue and if that doesn't work to contact the council about the noise complaint.
Yahoo
20-05-2025
- Business
- Yahoo
Avicanna Announces Sponsorship of Pilot Phase II Clinical Study Osteoarthritis Pain
Multi-centre, blinded, randomized placebo-controlled investigator initiated study, to be led by Dr. Hance Clarke and conducted at University Health Network TORONTO, May 20, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. ('Avicanna' or 'Company') (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, is pleased to announce it has entered into a Sponsored Research Agreement to sponsor an investigator initiated study on 'The Effectiveness of Oral Cannabis Extracts for Osteoarthritic Pain: An Internal Pilot, Placebo Controlled, Blinded Randomized Multicentre Trial' ('RCT'). The RCT is led Hance Clarke, MD, FRCPC, PhD as the principal investigator ('Dr. Clarke' or 'Principal Investigator') who is the medical director of the Pain Research Unit, and a clinician at University Health Network and is anticipated to start in the Fall of 2025. The primary objective of the RCT is to determine the feasibility of a blinded, randomized, placebo-controlled, 3-arm, parallel group trial of oral cannabinoids for improving pain interference in patients with hip and/or knee osteoarthritis. Specifically, the RCT will look to discover whether the planned definitive RCT is feasible with respect to patient enrollment, protocol adherence, and data completeness. The RCT is funded by a Canadian Institutes of Health Research ('CHIR') grant and is sponsored by Avicanna that is providing its proprietary CBD and THC capsules produced under Good Manufacturing Practices ('GMP') for the trial. About Avicanna: Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform including R&D and clinical development leading to the commercialization of more than thirty proprietary, evidence-based finished products and supporting four commercial stage business pillars. Medical Cannabis formulary (RHO Phyto™): The formulary offers a diverse range of proprietary products including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids, supported by ongoing patient and medical community education. RHO Phyto is an established brand in Canada currently available nationwide across several channels and expanding into new international markets. Medical cannabis care platform ( is a medical cannabis care platform formed with the aim to better serve medical cannabis patients' needs and enhance the medical cannabis patients' journey. is operated by Northern Green Canada Inc. and features a diverse portfolio of products and bilingual pharmacist-led patient support programs. also provides specialty services to distinct patient groups such as veterans and collaborates with public and private payers for adjudication and reimbursement. provides educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens. Pharmaceutical pipeline: Leveraging Avicanna's scientific platform, vertical integration, and real-world evidence, Avicanna has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. These cannabinoid-based candidates aim to address unmet needs in the areas of dermatology, chronic pain, and various neurological disorders. Active pharmaceutical ingredients (Aureus Santa Marta™): Active pharmaceutical ingredients supplied by the Company's majority owned subsidiary Santa Marta Golden Hemp SAS ('SMGH') is a commercial-stage business dedicated to providing various forms of high-quality CBD, THC and CBG to the Company's international partners for use in the development and production of food, cosmetics, medical, and pharmaceutical products. SMGH also forms part of the Company's supply chain and is a source of reliable input products for its consumer retail, medical cannabis, and pharmaceutical products globally. SOURCE Avicanna Inc. Stay Connected For more information about Avicanna, visit our website or contact Ivana Maric by email at info@ Cautionary Note Regarding Forward-Looking Information and Statements This news release contains 'forward-looking information' within the meaning of applicable securities laws. Forward-looking information contained in this news release may be identified by the use of words such as, 'may', 'would', 'could', 'will', 'likely', 'expect', 'anticipate', 'believe', 'intend', 'plan', 'forecast', 'project', 'estimate', 'outlook' and other similar expressions. Forward-looking information contained in this news release includes, without limitation, statements related to the Offering, the use of proceeds of the Offering, the receipt of all approvals of the Toronto Stock Exchange in connection with the Offering, statements with respect to the Company's future business operations, the opinions or beliefs of management and future business goals. Although the Company believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company's annual information form dated April 11, 2025, filed with the Canadian securities regulators and available under the Company's profile on SEDAR+ at The statements in this news release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
